Lunai Bioworks Inc

Lunai Bioworks Inc has a market capitalization of $10.03 million and a price-to-book ratio of 0.08, indicating a significant discount to its book value. The company's liquidity position is weak, with a current ratio of 0.07, suggesting limited ability to meet short-term obligations. The company's operating cash flow is negative at -$10.97 million, and free cash flow is -$15.72 million, indicating a lack of cash generation from operations. Profitability metrics are negative, with a return on equity of -11.92% and a return on assets of -9.64%, both well below the industry median for biotechnology firms. The company reported a net loss of $15.73 million and an operating loss of $18.29 million, reflecting ongoing operational challenges. The debt-to-equity ratio is low at 0.02, indicating minimal leverage, but the company's negative net cash position raises concerns about liquidity. The company's revenue is not disclosed in the provided data, and no specific geographic or segment breakdown is available. However, the lack of detailed revenue concentration data suggests the company may be in an early stage of development or may not have disclosed such information in its latest filings. Looking ahead, the company is expected to continue facing financial challenges, with no specific growth trajectory provided in the data. The negative operating and net income, combined with the lack of cash flow generation, suggests the company is in a capital-intensive growth phase or facing operational inefficiencies. The company's risk profile is characterized by medium liquidity risk and low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's vulnerability to liquidity shocks. The low dilution risk suggests that the company is not currently issuing shares at a high rate, but the potential for future dilution remains a concern. Recent events and filings do not provide specific details on the company's operations or strategic direction. The absence of recent earnings calls or investor presentations suggests limited transparency or engagement with the market.